zoledronic acid has been researched along with Conus Medullaris Syndrome in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 27 (72.97) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cruz, C; Malamud, S; Miyashita, H | 1 |
| Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Lüftner, D; Niepel, D; Steger, GG | 1 |
| Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L | 1 |
| Harada, H; Hosaka, S; Katagiri, H; Murata, H; Niwakawa, M; Takahashi, M; Wasa, J | 1 |
| Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
| Bajory, Z; Bouzid, M; Cathomas, R; El Ghoneimy, A; Gillessen, S; Goncalves, F; Kacso, G; Kramer, G; Lesniewski-Kmak, K; Milecki, P; Pacik, D; Tantawy, W | 1 |
| Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| Manabe, J; Miyata, S; Orita, Y; Sugitani, I; Takao, S; Toda, K | 1 |
| Beer, TM; Graff, JN | 1 |
| Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ | 1 |
| Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Costa, L; Lipton, A | 1 |
| Van Poznak, C | 1 |
| Brown, J; Clark, K; Gregory, W; Hayward, K; Jagdev, S; McParland, L; Newsham, A; Rogerson, S; Selby, P; Woodward, E | 1 |
| Eastham, J; Saad, F | 1 |
| Berenson, J; Dimopoulos, MA; Terpos, E | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
| Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP | 1 |
| Henk, HJ; Kaura, S | 1 |
| Henk, H; Kaura, S; Teitelbaum, A | 1 |
| Beaujeux, R; Boujan, F; Boyer, P; Cebula, H; Froelich, S | 1 |
| Birkholz, K; Gruenwald, V; Kindler, M; May, C; Miller, K; Ruebel, A; Schultze-Seemann, W; Schulze, M; Stenzl, A; Strauss, A; Tunn, UW; Wirth, MP; Zantl, N | 1 |
| Bajrovic, A; Hakim, SG; Karstens, JH; Rades, D; Rudat, V; Schild, SE; Veninga, T | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
| Huang, B; Li, CL; Liang, R; Pan, LH; Qian, W; Zheng, WW; Zhong, JH; Zhu, M | 1 |
| Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M | 1 |
| Cook, R; Major, PP | 1 |
| Lipton, A; Seaman, J; Zheng, M | 1 |
| Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J | 1 |
| Khuri, F; Saba, N | 1 |
| Saad, F | 1 |
| Gogia, N; Kumar, R; Mahapatra, M; Malik, M; Pillai, LS; Puri, T; Sharma, DN | 1 |
9 review(s) available for zoledronic acid and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Therapeutic approaches for protecting bone health in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid | 2018 |
Management of bone metastases in patients with castration-resistant prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Interdisciplinary Communication; Male; Medical Oncology; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2014 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid | 2017 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2011 |
Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Musculoskeletal Pain; Pain Measurement; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2013 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid | 2005 |
13 trial(s) available for zoledronic acid and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Disease-Free Survival; Female; Fractures, Spontaneous; Humans; Middle Aged; Risk Assessment; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2020 |
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid | 2014 |
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid | 2017 |
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Egypt; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pain; Placebo Effect; Prospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Pain; Pain Measurement; Prostatic Neoplasms; Spinal Cord Compression; Survival Rate; Zoledronic Acid | 2010 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Spinal Cord Compression; Tomography, X-Ray Computed; Zoledronic Acid | 2012 |
Impact of zoledronic acid on control of metastatic spinal cord compression.
Topics: Aged; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Comorbidity; Diphosphonates; Female; Germany; Humans; Imidazoles; Male; Middle Aged; Prevalence; Radiotherapy, Conformal; Risk Factors; Spinal Cord Compression; Spinal Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Female; Fractures, Bone; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Placebos; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2004 |
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
Topics: Aged; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Pain; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2005 |
15 other study(ies) available for zoledronic acid and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2021 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Chemoradiotherapy; Female; Fractures, Spontaneous; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Spinal Cord Compression; Sunitinib; Survival Rate; Treatment Outcome; Zoledronic Acid | 2018 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Pain; Peptides; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Spinal Cord Compression; Thyroid Neoplasms; Zoledronic Acid | 2015 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multicenter Studies as Topic; Pain; Pain Measurement; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Predicting skeletal complications in metastatic breast cancer raises challenges.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Pain; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Skeletal complications and survival in renal cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Spinal Cord Compression; Survival Analysis; Time Factors; Zoledronic Acid | 2011 |
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2011 |
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Insurance Claim Review; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Spinal Cord Compression; United States; Zoledronic Acid | 2012 |
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Neoplasms; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2012 |
[Giant cell tumor of the C2 colonized by an aneurismal bone cyst. Report of case].
Topics: Accidents, Home; Adult; Bone Cysts, Aneurysmal; Bone Density Conservation Agents; Bone Plates; Cervical Vertebrae; Diphosphonates; Embolization, Therapeutic; Fracture Fixation, Internal; Fractures, Spontaneous; Giant Cell Tumors; Humans; Imidazoles; Ligation; Magnetic Resonance Imaging; Male; Odontoid Process; Spinal Cord Compression; Spinal Fractures; Spinal Neoplasms; Spinal Stenosis; Tomography, X-Ray Computed; Torticollis; Vertebral Artery; Zoledronic Acid | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2013 |
Paraplegia due to extramedullary hematopoiesis in thalassemia treated successfully with radiation therapy.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Calcium; Cobalt Radioisotopes; Contraindications; Decompression, Surgical; Diphosphonates; Epidural Space; Folic Acid; Fractures, Spontaneous; Hematopoiesis, Extramedullary; Humans; Imidazoles; Male; Osteoporosis; Paraplegia; Radioisotope Teletherapy; Spinal Cord Compression; Zoledronic Acid | 2007 |